Hexachlorophene

Summary

Hexachlorophene (CHEMBL496) is an approved small-molecule antiseptic drug (ATC D08AE01) targeting NAPEPLD.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D08AE01
• Targets: 1 (NAPEPLD)
• Clinical trials: 6
• Chemistry: 406.9 Da · C13H6Cl6O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL496
Name	Hexachlorophene
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3598
ChEBI	CHEBI:5693
ATC	D08AE01
Molecular formula	C13H6Cl6O2
Molecular weight	406.9
InChIKey	ACGUYXCXAPNIKK-UHFFFAOYSA-N

SMILES: C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl

IUPAC name: 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol

ChEBI definition: An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.

Pharmacological roles (ChEBI): antiseptic drug, acaricide, antibacterial agent, antifungal agrochemical.

Also known as: Dial, E-z scrub, Gamophen, Germa-medica, Germa-medica “mg”, Hexa-germ, Hexachlorophene, Hexaclorofeno, Hexascrub, NSC-49115, Phiso-scrub, Phisohex

Patent coverage: 8,380 distinct patent families (26,164 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 24,870 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NAPEPLD	N-Acylphosphatidylethanolamine-phospholipase D	Inhibition	5.01	0%	Q6IQ20

Broader ChEMBL bioactivity targets: 86 (assay-derived). Sample: Transitional endoplasmic reticulum ATPase, Heat shock cognate 71 kDa protein, Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Streptokinase A, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM.

Bioactivity

ChEMBL activities: 80 potent at pChembl ≥ 5 of 129 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK14	7.06	IC50	87.6	nM	CHEMBL_ACT_7655910
ESR2	7.01	IC50	98.27	nM	CHEMBL_ACT_4418448
MAPK1	6.71	IC50	196	nM	CHEMBL_ACT_7655908
P10520	6.7	EC50	202	nM	CHEMBL_ACT_4929491
ADORA3	6.44	Ki	361.1	nM	CHEMBL_ACT_7653710
LMNA	6.35	Potency	446.7	nM	CHEMBL_ACT_4902172
ADORA3	6.2	IC50	638.9	nM	CHEMBL_ACT_7653709
PTGS2	6.19	IC50	644.3	nM	CHEMBL_ACT_7653771
ADRA1A	6.15	AC50	704.8	nM	CHEMBL_ACT_25218690
PGR	6.13	AC50	746.9	nM	CHEMBL_ACT_25204101
EGFR	6.13	IC50	748.6	nM	CHEMBL_ACT_7655914
HSP90AA1	6.11	AC50	770	nM	CHEMBL_ACT_7450362
ADORA2A	6.04	Ki	906	nM	CHEMBL_ACT_7653708
ADRA2C	5.99	Ki	1014	nM	CHEMBL_ACT_7653724
CYP2C19	5.91	IC50	1226	nM	CHEMBL_ACT_7653777
HSPD1	5.89	IC50	1300	nM	CHEMBL_ACT_19209380
CYP1A2	5.88	IC50	1313	nM	CHEMBL_ACT_7653773
TACR2	5.86	Ki	1380	nM	CHEMBL_ACT_7655953
NAPEPLD	5.8	IC50	1600	nM	CHEMBL_ACT_22806869
ADORA2A	5.79	IC50	1614	nM	CHEMBL_ACT_7653707
ADORA3	5.76	AC50	1732	nM	CHEMBL_ACT_25198568
P9WMR3	5.74	AC50	1815	nM	CHEMBL_ACT_6555085
PTGS1	5.72	AC50	1884	nM	CHEMBL_ACT_25205034
LMNA	5.7	Potency	1995	nM	CHEMBL_ACT_3626849
ADRA2A	5.69	Ki	2061	nM	CHEMBL_ACT_7653720
ESR1	5.67	IC50	2162	nM	CHEMBL_ACT_4536451
SLC6A4	5.64	Ki	2311	nM	CHEMBL_ACT_7655943
HTR2C	5.62	Ki	2412	nM	CHEMBL_ACT_7655935
MAPK3	5.61	IC50	2484	nM	CHEMBL_ACT_7655906
LCK	5.61	IC50	2432	nM	CHEMBL_ACT_7655920

Target pathways

Aggregated over 1 target gene(s): NAPEPLD.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	NAPEPLD
Retinoid cycle disease events	1	NAPEPLD
Biosynthesis of A2E, implicated in retinal degradation	1	NAPEPLD
Diseases associated with visual transduction	1	NAPEPLD
Diseases of the neuronal system	1	NAPEPLD

Dominant GO biological processes

GO term	Targets
temperature homeostasis	1
phospholipid catabolic process	1
response to isolation stress	1
host-mediated modulation of intestinal microbiota composition	1
positive regulation of inflammatory response	1
N-acylethanolamine metabolic process	1
N-acylphosphatidylethanolamine metabolic process	1
positive regulation of brown fat cell differentiation	1
negative regulation of eating behavior	1
lipid metabolic process	1
phospholipid metabolic process	1
lipid catabolic process	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	5
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03652818	PHASE2	COMPLETED	Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
NCT02627235	Not specified	COMPLETED	The Deep South IVR-based Active Lifestyle Study
NCT03859102	Not specified	UNKNOWN	Enhanced Recovery After Cardiac Surgery
NCT04174209	Not specified	COMPLETED	CHOICE OF SUBJECTIVE OCULAR REFRACTION TECHNIQUE AND CORNEAL TOPOGRAPHY OF KERATOCONUS
NCT05762978	Not specified	COMPLETED	Evaluation of Negative Inspiratory Flow in Children With Acute Asthma
NCT06070402	Not specified	UNKNOWN	Use of a Voice Assistant to Improve Mental Health in Older People

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
Orlistat	PubChem	Approved	NAPEPLD